RxDoctor Payments Data

Kevin Bordelon

Internal Medicine · Marksville, LANPI 1972506491

Payments from drug & device makers

$1,526in general payments, 2019–2025

Across 88 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$417
  • Lilly USA, LLC$346
  • AstraZeneca$189
  • Boehringer Ingelheim$85
  • Exact Sciences$69
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$53
  • plus $367 from 12 others

What the payments were for

  • Food & beverage$1,526100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,526 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide221$240,966
TrulicityDulaglutide67$71,098
EliquisApixaban57$63,764
JardianceEmpagliflozin51$56,496
MounjaroTirzepatide44$55,347
FarxigaDapagliflozin Propanediol25$27,609
XareltoRivaroxaban16$25,223
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$24,789
JanuviaSitagliptin Phosphate15$19,916
Tresiba Flextouch U-100Insulin Degludec31$17,824
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$17,514
Soliqua 100-33Insulin Glargine/Lixisenatide16$13,897
Tresiba Flextouch U-200Insulin Degludec18$11,225
LinzessLinaclotide13$8,934
Dexlansoprazole DrDexlansoprazole31$8,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$417$240,966221 claims
Lilly USA, LLCTrulicity, Mounjaro$346$126,445111 claims
Boehringer IngelheimJardiance$85$56,49651 claims
GSKTrelegy Ellipta, Anoro Ellipta$33$42,30351 claims
AstraZenecaFarxiga$189$27,60925 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$50$13,89716 claims
AbbVieLinzess, Synthroid$43$11,24241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Marksville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →